Affymetrix Licenses Patents to Invitrogen for Manufacture of Nucleic Acid Arrays | GenomeWeb
NEW YORK (GenomeWeb News) - Affymetrix and Invitrogen said today that Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents.
Under the agreement, Invitrogen will now be allowed to "manufacture and sell spotted nucleic acid microarrays in the research field," the companies said. Financial details of the license were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.